InflaRx N.V. Common Stock
Exchange: NASDAQ
Symbol: IFRX
SEC CIK: 0001708688
Phone: 49 3641 508180
WINZERLAER STR. 2
JENA 2M 07745
CEO:
|
Price when page updated: 1.41 Date: 2023-11-30
Company Website:
www.inflarx.de
|
_Description: InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.
IPO YEAR:
2017
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
76302897.00
|
Beta:
1.973792536404613
|
52 Week High:
6.88
|
52 Week Low:
2.23
|
52 Week Change:
-0.07920792079207906
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
43228415
|
Dividend Rate:
0
|
Dividend Yield:
10.12%
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
N/A
|
Float:
0
|
return on Equity:
-
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
N/A
|
ttmEPS:
0
|
Revenue:
N/A
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
42.95%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
-
|
Return on Assets:
-
|
Return on Capital:
|
Profit Margin:
-
|
Price to Sales:
-
|
Price To Book:
-
|
Short Ratio:
0.32
|
PE Ratio:
0
|
Employees:
49
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__InflaRx N.V. Common Stock [ IFRX ].
__Note: Some Links might not have information for the company.
|
|
